Treace Medical Concepts, Inc.
NNASDAQ:TMCIRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Treace Medical Concepts, Inc. (Nasdaq: TMCI) develops and markets minimally invasive foot and ankle medical devices designed for surgical correction of bunion deformities and related midfoot and forefoot pathologies. The company offers a comprehensive portfolio of proprietary orthopedic products, including the Lapiplasty 3D Bunion Correction System, the CrossRoads Fixation System, the SpeedPlate Fixation Systems, the Adductoplasty Lapidus Plate, the Hammertoe Fixation Systems, and the Mini-Bunion Kit; these systems utilize patented nitinol compression technology and titanium implants to enable reproducible, stable corrections with reduced complication risks. Treace serves orthopedic foot and ankle surgeons and podiatric surgeons primarily in the United States, with operations focused on the domestic market from its headquarters in Ponte Vedra Beach, Florida, where the company was founded in 2014. In recent developments, Treace expanded its product offerings with the launch of the Mini-Bunion System in 2024 and the Adductoplasty Lapidus Plate in early 2025, enhancing minimally invasive options for juvenile and adult bunion corrections; the company also strengthened its commercial infrastructure through surgeon education programs and reported robust procedure growth amid ongoing reimbursement advancements.
Company News
Treace to Present at the Stifel 2026 Healthcare Conference
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts Q2 Earnings Call Highlights
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
Treace to Present at the Sidoti Small Cap Conference
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts Reports First Quarter 2026 Financial Results